Skip to main content
. 2021 Feb 19;18(4):2026. doi: 10.3390/ijerph18042026

Table 1.

Baseline characteristics, clinical findings, and pregnancy outcomes of the study population.

Variables Total
(n = 115)
Delivery
≥32 Weeks
(n = 106)
Delivery
<32 Weeks
(n = 9)
p-Value
Maternal age, years 34 (25–42) 34 (25–42) 35 (28–39) 0.415
Prepregnancy BMI, kg/m2 22.9 (19.0–36.2) 22.9 (19.0–36.2) 22.8 (20.4–27.3) 0.577
Current smoking 1 (0.9%) 1 (0.9%) 0 (0.0%) 1.000
Multiparity 57 (49.6%) 54 (50.9%) 3 (33.3%) 0.655
Prior miscarriage 39 (33.9%) 35 (33.0%) 4 (44.4%) 0.803
Prior cesarean section 20 (17.4%) 19 (17.9%) 1 (11.1%) 0.999
Prior preterm birth 8 (7.0%) 8 (7.5%) 0 (0.0%) 0.999
IVF-ET 17 (14.8%) 14 (13.2%) 3 (33.3%) 0.227
Prior conization 10 (8.7%) 9 (8.5%) 1 (11.1%) 0.844
Pregestational diabetes mellitus 2 (1.7%) 1 (0.9%) 1 (11.1%) 0.192
GDM 11 (9.9%) 10 (9.7%) 1 (12.5%) 0.852
Preeclampsia 2 (1.8%) 1 (1.0%) 1 (12.5%) 0.182
Chronic hypertension 3 (2.6%) 2 (1.9%) 1 (11.1%) 0.299
Thyroid disease 6 (5.2%) 4 (3.8%) 2 (22.2%) 0.098
GA at diagnosis 22 w 6 d
(16 w 1 d–28 w 6 d)
22 w 5 d
(16 w 1 d–28 w 6 d)
23 w 5 d
(17 w 0 d–26 w 3 d)
0.599
Cervical length, mm 22.0 (10.0–25.0) 22.0 (10.0–25.0) 20.5 (13.0–24.0) 0.103
Funneling 8 (7.0%) 6 (5.7%) 2 (22.2%) 0.176
Positive fibronectin 27 (35.5%) 22 (32.4%) 5 (62.5%) 0.256
Progesterone type
Vaginal suppository 110 (95.7%) 101 (95.3%) 9 (100.0%) 0.999
IM injection 5 (4.3%) 5 (4.7%) 0 (0.0%)
GA at delivery 38 w 2 d
(18 w 5 d–41 w 0 d)
38 w 3 d
(33 w 1 d–41 w 0 d)
27 w 0 d
(18 w 5 d–31 w 6 d)
<0.001
Cesarean delivery 62 (53.9%) 55 (51.9%) 7 (77.8%) 0.337
Birth weight, g 3040 (830–4030) 3110 (1760–4030) 1075 (830–1830) <0.001
Apgar score <7 at 5 min 3 (2.9%) 2 (2.1%) 1 (12.5%) 0.296
NICU admission 21 (20.4%) 13 (13.7%) 8 (100.0%) <0.001

Data are presented as the median (range) or number (%). BMI, body mass index; IVF-ET, in vitro fertilization-embryo transfer; GDM, gestational diabetes; GA, gestational age; IM, intramuscular; NICU, neonatal intensive care unit; w, weeks; d, days.